The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
Open accessAbstract
We explored whether breast cancer outcomes are associated with endoxifen and other metabolites of tamoxifen and examined potential correlates of endoxifen concentration levels in serum including cytochrome P450 2D6 (CYP2D6) metabolizer phenotype and body mass index (BMI). Concentration levels of tamoxifen, endoxifen, 4-hydroxytamoxifen (4OH-tamoxifen), and N-desmethyltamoxifen (ND-tamoxifen) were measured from samples taken from 1,370 patients with estrogen receptor (ER)-positive breast cancer who were participating in the Women's Healthy Eating and Living (WHEL) Study. We tested these concentration levels for possible associations with breast cancer outcomes and found that breast cancer outcomes were not associated with the concentration levels of tamoxifen, 4-hydroxytamoxifen, and ND-tamoxifen. For endoxifen, a threshold was identified, with women in the upper four quintiles of endoxifen concentration appearing to have a 26% lower recurrence rate than women in the bottom quintile (hazard ratio (HR) = 0.74; 95% confidence interval (CI), (0.55-1.00)). The predictors of this higher-risk bottom quintile were poor/intermediate metabolizer genotype, higher BMI, and lower tamoxifen concentrations as compared with the mean for the cohort as a whole. This study suggests that there is a minimal concentration threshold above which endoxifen is effective against the recurrence of breast cancer and that ~80% of tamoxifen takers attain this threshold.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Pierce, J. P., Natarajan, L., Caan, B. J., Parker, B. A., Greenberg, E. R., Flatt, S. W., Rock, C. L., Kealey, S., Al-Delaimy, W. K., Bardwell, W. A., et al. (2007) · JAMA · doi:10.1001/jama.298.3.289 · Cited by 734
Self-citationBORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Self-citationJohnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., & Brøsen, K. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050163 · Cited by 321
Pandya, K. J., Raubertas, R. F., Flynn, P. J., Hynes, H. E., Rosenbluth, R. J., Kirshner, J. J., Pierce, H. I., Dragalin, V., & Morrow, G. R. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00004 · Cited by 310
Pierce, J. P., Faerber, S., Wright, F. A., Rock, C. L., Newman, V., Flatt, S. W., Kealey, S., Jones, V. E., Caan, B. J., Gold, E. B., et al. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00241-6 · Cited by 246
Self-citationDecensi, A., Robertson, C., Viale, G., Pigatto, F., Johansson, H., Kisanga, E. R., Veronesi, P., Torrisi, R., Cazzaniga, M., Mora, S., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.11.779 · Cited by 221
Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse
Hess, K. R., Pusztai, L., Buzdar, A. U., & Hortobagyi, G. N. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1022166517963 · Cited by 197
Tableman, M., & Kim, J. S. (2003) · Chapman & Hall/CRC eBooks · doi:10.1201/b16988 · Cited by 160
Resampling and cross-validation techniques: a tool to reduce bias caused by model building?
Schumacher, M. C., Holländer, N., & Sauerbrei, W. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19971230)16:24<2813::aid-sim701>3.0.co;2-z · Cited by 143
Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance
Jordan, V. C., & Chem, C. (1982) · Breast Cancer Research and Treatment · doi:10.1007/bf01806449 · Cited by 138
Tamoxifen, hot flashes and recurrence in breast cancer
Mortimer, J. E., Flatt, S. W., Parker, B. A., Gold, E. B., Wasserman, L. M., Natarajan, L., Pierce, J. P., & For the WHEL Study Group (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9612-x · Cited by 133
Self-citationHazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
Dignam, J. J., Dukić, V., Anderson, S., Mamounas, E. P., Wickerham, D. L., & Wolmark, N. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0200-5 · Cited by 121
Anderson, W. F., Chen, B. E., Jatoi, I., & Rosenberg, P. S. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9231-y · Cited by 90
Time-Varying Effects of Prognostic Factors Associated With Disease-Free Survival in Breast Cancer
Natarajan, L., Pu, M., Parker, B. A., Thomson, C. A., Caan, B. J., Flatt, S. W., Madlensky, L., Hájek, R., Al‐Delaimy, W. K., Saquib, N., et al. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp077 · Cited by 51
Self-citationTamoxifen, Soy, and Lifestyle Factors in Asian American Women With Breast Cancer
Wu, A. H., Pike, M. C., Williams, L. D., SPICER, D. V., Tseng, C.-C., Churchwell, M. I., & Doerge, D. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5023 · Cited by 42
Self-citationThe Impact of CYP2D6 Genotyping on Tamoxifen Treatment
Ferraldeschi, R., & Newman, W. G. (2010) · Pharmaceuticals · doi:10.3390/ph3041122 · Cited by 25
Selective Serotonin-Reuptake Inhibitors for the Treatment of Hot Flashes
Koch, Y. D. S., & Ernst, M. E. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d512 · Cited by 10
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Regan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Goetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl‐Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1007 · Cited by 336
Daphnia magna model in the toxicity assessment of pharmaceuticals: A review
Tkaczyk, A., Bownik, A., Dudka, J., Kowal, K., & Ślaska, B. (2021) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.143038 · Cited by 328
Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., Veal, G., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 296
Metadata
- Authors
- Madlensky, L., Natarajan, L., Tchu, S., Pu, M., Mortimer, J., Flatt, S. W., Nikoloff, D. M., Hillman, G., Fontecha, M. R., Lawrence, H. J., Parker, B. A., Wu, A. H. B., & Pierce, J. P.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-03-23
- Volume
- 89
- Issue
- 5
- Pages
- 718-725
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2135502243
- Cited by
- 334
- References
- 22
- FWCI
- 27.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.